1 / 3

Gastroesophageal Reflux Disease (GERD) Therapeutics Market Key Participants, Trends and Revenue Analysis Report, 2025

The global Gastroesophageal Reflux Disease (GERD) therapeutics market is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%. <br>

tom_clark
Download Presentation

Gastroesophageal Reflux Disease (GERD) Therapeutics Market Key Participants, Trends and Revenue Analysis Report, 2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Gastroesophageal Reflux Disease (GERD) Therapeutics Market Revenue Drivers, Growth Opportunities, Supply Chain Analysis and Forecast Research Report Till 2025 “The global Gastroesophageal Reflux Disease (GERD) therapeutics market is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%.” The global Gastroesophageal Reflux Disease (GERD) Therapeutics Market research report provides complete insights on industry scope, global trends, regional estimates, key application, competitive landscape and financial performance of prominent players. It also offers ready, data-driven answers to several industry-level questions. This study enables numerous opportunities for the market players to invest in research and development. Market Overview: The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%. Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is major restraining factors for this market. Upon loss of patent protection of formerly leading branded drugs, generic molecules with low-price can ingest the sales of the branded ones up to 90%. Rising number of companies being exposed to price scrutiny associated with shift in the focus of government on the promotion of consumer convenience will stimulate further reduction of drug prices. Although market turnover is affected by the expiration of major patents and the demand of drugs used to reduce acid, due to the increasing prevalence of heartburn, is anticipated to increase in the upcoming years.

  2. Key Players: Takeda Pharmaceutical Co., Ltd. AstraZeneca PLC Eisai Co., Ltd. GlaxoSmithKline PLC. Johnson & Johnson Services, Inc. Daewoong Pharmaceutical Co., Ltd Ironwood Pharmaceuticals, Inc. Request free sample to get complete analysis of top-performing companies @ https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics- market/request-sample Nevertheless, the advent of devices which are minimally invasive to address anatomical defects are gaining popularity coupled with supportive evidence from clinical data for performing various procedures including trans oral fundoplication, which helps in preventing reflux of non-acid and acid contents. The adoption of these devices have been further reinforced in the U.S. in 2016 with the advent of a CPT code (43210) which helps in facilitating reimbursement process. Application Outlook: Antacids H2 Receptor Blockers Proton Pump Inhibitors (PPIs) Pro-kinetic agents Regional Insights: In 2016, the largest region was found to be North America in terms of share for GERD market. Every year, GERD symptoms are experienced by more than 80 million people in the U.S., of which, approximately 25 million patients suffer from acid reflux and heartburn daily and approximately 60 million patients monthly. Moreover, outpatient clinic visits for GERD disorder in the U.S. has been increased in the past few years because of the more prone geriatric population to develop acid reflux and heartburn. On the contrary, the Asia Pacific is estimated to witness the fastest growth rate. The increasing geriatric population and dietary and lifestyle risk factors such as diet with high fat and obesity, is anticipated to drive the growth. In developing countries, the inclination towards self-medication is quickly increasing because of the affordability and availability of OTC antacids as in China and India. Browse Related Category Research Reports @ https://blog.naver.com/tomclark

  3. Get in touch At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions. Contact Person: Ryan Manuel Research Support Specialist, USA Email: ryan@millioninsights.com Asia Pacific Global Headquarters Million Insights Million Insights Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016 India Felton Office Plaza 6265 Highway 9 Felton, California 95018, United States Phone: 1-408-610-2300 Email: sales@millioninsights.com Phone: 91-20-65300184 Email: sales@millioninsights.com

More Related